Clinical Response to Gefitinib Retreatment of Lung Adenocarcinoma Patients Who Benefited from An Initial Gefitinib Therapy: A Retrospective Analysis

Background and objective Gefitinib is an epidermal growth factor receptor-tyrosine Shakes kinase inhibitor (EGFR-TKI) that has been widely used for the treatment of non-small cell lung cancer (NSCLC).It is most effective in women, as well as in patients who have never smoked, have pulmonary adenocarcinomas, or are of Asian origin.Several treatment

read more